Group structure
5 companies in 3 countries
United States1
Headquarters not stated1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Loading your page…
Loading your page…
5 companies in 3 countries
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine of every company in the group, current ones first.
25 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ALA-SCALP2% · Lotion | Hydrocortisone | United States | Marketed | 1973 |
| BETAPACE120mg | 160mg | 240mg | 320mg | 80mg · Tablet | Sotalol | United States | Marketed | 1992 |
| BETAPACE AF100mg | 120mg | 160mg | 40mg | 60mg | 80mg · Tablet | Sotalol | United States | Marketed | 2000 |
| BRISDELLE7.5mg base · Capsule | Paroxetine | United States | Marketed | 2013 |
| CLODERM0.1% · Cream | Clocortolone pivalate | United States | Marketed | 1977 |
| CROTAN10% · Lotion | Crotamiton | United States | Marketed | 1981 |
| ESBRIET267MG | 534MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 801MG · Tablet | Pirfenidone | United States | Marketed | 2017 |
| ESBRIET267mg · Capsule | Pirfenidone | United States | Marketed | 2014 |
| ETHYOL375mg/vial | 500mg/vial · Injectable | Amifostine | United States | Marketed | 1995 |
| IMURAN25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 50MG · Tablet | Azathioprine | United States | Marketed | 1968 |
| LOTRONEX0.5mg base | 1mg base · Tablet | Alosetron | United States | Marketed | 2000 |
| MICORT-HC2.5% | 2% · Cream | Hydrocortisone | United States | Marketed | 2001 |
| MOTOFEN0.025mg; 1mg · Tablet | Atropine, Difenoxin | United States | Marketed | 1978 |
| MOTOFEN HALF-STRENGTH0.025mg; 0.5mg · Tablet | Atropine, Difenoxin | United States | Not marketed | 1978 |
| NAFTIN1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 2% · Cream | Naftifine | United States | Marketed | 1988 |
| NAFTIN1% | 2% · GEL | Naftifine | United States | Marketed | 1990 |
| PRAMOSONE0.5%; 1% | 1%; 1% | 2.5%; 1% · Lotion | Hydrocortisone, Pramocaine | United States | Marketed | 1973 |
| PRAMOSONE0.5%; 1% | 1%; 1% · Cream | Hydrocortisone, Pramocaine | United States | Marketed | 1976 |
| RIDAURA3MG · Capsule | Auranofin | United States | Marketed | 1985 |
| ZANAFLEX2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 4MG BASE · Tablet | Tizanidine | United States | Marketed | 1996 |
| ZANAFLEX2mg base | 4mg base | 6mg base · Capsule | Tizanidine | United States | Marketed | 2002 |
| DISFLATYL DROPS 40MG-ML | Dimethicone | Saudi Arabia | Authorised | |
| DISFLATYL TAB | Dimethicone | Saudi Arabia | Authorised | |
| Cinainu | Dry aqueous extract paullinia cupana seed, Dry hydroethanolic extract theobroma cacao seed, Liquid ethanolic extract cent allium cepa fresh bulb and citrus limon fresh fruit | EU (EMA) | Refused | |
| EVERWIPE DISINFECTANT WIPES0.14 % + 0.14 % · Wipe | Alkyl dimethyl ethylbenzyl ammonium, Benzalkonium | Canada | Cancelled |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 21 | 21 | 0 | CompaniesAll medicines |
| Saudi Arabia | 2 | 2 | 0 | CompaniesAll medicines |
| Canada | 1 | 0 | 1 | CompaniesAll medicines |
| European Union (EMA) | 1 | 0 | 1 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Report an error or request removalCorrections from the company itself are welcome.
Well-known pharmaceutical groups, each with all its companies.